Incidence of death or disability at 6 months after ECMO in Australia: a prospective, multicentre, registry-embedded cohort study

Carol L Hodgson, Alisa M Higgins, Michael J Bailey, Shannah Anderson, Stephen Bernard, Bentley J Fulcher, Denise Koe, Natalie J Linke, Jasmin V Board, Daniel Brodie, Heidi Buhr, Aidan J C Burrell, D James Cooper, Eddy Fan, John F Fraser, David J Gattas, Ingrid K Hopper, Sue Huckson, Edward Litton, Shay P McGuinness, Priya Nair, Neil Orford, Rachael L Parke, Vincent A Pellegrino, David V Pilcher, Jayne Sheldrake, Benjamin A J Reddi, Dion Stub, Tony V Trapani, Andrew A Udy, Ary Serpa Neto et al. The Lancet Respiratory Medicine,2022,ISSN 2213-2600 DOI: doi.org/10.1016/S2213-2600(22)00248-X

Background: Extracorporeal membrane oxygenation (ECMO) is an invasive procedure used to support critically ill patients with the most severe forms of cardiac or respiratory failure in the short term, but long-term effects on incidence of death and disability are unknown. We aimed to assess incidence of death or disability associated with ECMO up to 6 months (180 days) after treatment.